Datapoint: FDA Approves Merck’s Tepmetko for NSCLC Mutation

The FDA last week approved Merck KGaA’s Tepmetko for the treatment of non-small cell lung cancer with MET exon 14 skipping mutations, an aggressive form of the disease which affects between 3% and 4% of NSCLC patients, according to a press release from the drugmaker. The drug will have to face off against Novartis’s Tabrecta, which scored the first-in-class nod in May 2020. Under the pharmacy benefit, Tabrecta currently holds preferred formulary placement for 4% of covered lives, growing to 14% with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 2/8/21

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 25

Datapoint: Kaiser Dominates 2022 Star Ratings

https://www.mmitnetwork.com/wp-content/uploads/2021/08/post-default-img.jpg
October 18

Datapoint: AmeriHealth Caritas to Enter Exchange Market

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
October 14

Datapoint: Ochsner to Launch MA Org in Louisiana

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today